Pharmaceutical Executive-01-01-2005

Sponsored and produced by Focus Limited.

Citing cherry-picked patients, unrealistic dosing, and placebo control, payers will increasingly require that the proof for payment of drugs must come from head-to-head trials.

Heading the WHO list are pandemic influenza and antibiotic-resistant bacterial infections. Together the two could kill millions.